157 related articles for article (PubMed ID: 37361582)
1. Case Report: Effects of multiple myeloma therapy on essential thrombocythemia and vice versa: a case of synchronous dual hematological malignancy.
Krishnan N; Price R; Kotchetkov R
Front Oncol; 2023; 13():1213942. PubMed ID: 37361582
[TBL] [Abstract][Full Text] [Related]
2. Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia.
Abdelghani M; Hammami H; Zidi W; Amouri H; Othmen HBH; Farrah A; Menif S
J Clin Lab Anal; 2022 Aug; 36(8):e24522. PubMed ID: 35754115
[TBL] [Abstract][Full Text] [Related]
3. Management of Essential Thrombocythemia in a Patient With a History of Thrombotic Thrombocytopenic Purpura.
Johnson S; Lee A; Robertson Q; Wagner SD
Cureus; 2024 Apr; 16(4):e57716. PubMed ID: 38716021
[TBL] [Abstract][Full Text] [Related]
4. Clinical and Hematological Relevance of JAK2V617F, CALR, and MPL Mutations in Vietnamese Patients with Essential Thrombocythemia.
Vu HA; Thao TT; Dong CV; Vuong NL; Chuong HQ; Van PNT; Nghia H; Binh NT; Dung PC; Xinh PT
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2775-2780. PubMed ID: 31554376
[TBL] [Abstract][Full Text] [Related]
5. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
[TBL] [Abstract][Full Text] [Related]
6. Synchronous detection of multiple myeloma and acute myeloid leukemia: A diagnostic and therapeutic challenge.
Maral S; Albayrak M; Sahin O; Ozturk HBA; Han U; Falay M
J Oncol Pharm Pract; 2021 Mar; 27(2):464-469. PubMed ID: 33620259
[TBL] [Abstract][Full Text] [Related]
7. [Clinical Analysis of 66 Patients with Essential Thrombocytopenia].
Zhang LJ; Shi YY; Chen Y; Gan YM; Shi WT; Chen KK; Ding BH; He ZM; Wang CL; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1321-1325. PubMed ID: 32798420
[TBL] [Abstract][Full Text] [Related]
8. Xanthoma-like Skin Changes in an Elderly Woman with a Normal Lipid Profile.
Nockowski P; Woźniak Z; Reich A; Maj J
Acta Dermatovenerol Croat; 2017 Jul; 25(2):167-169. PubMed ID: 28871936
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Michiels JJ; Kutti J; Stark P; Bazzan M; Gugliotta L; Marchioli R; Griesshammer M; van Genderen PJ; Brière J; Kiladjian JJ; Barbui T; Finazzi G; Berlin NI; Pearson TC; Green AC; Fruchtmann SM; Silver RT; Hansmann E; Wehmeier A; Lengfelder E; Landolfi R; Kvasnicka HM; Hasselbalch H; Cervantes F; Thiele J
Neth J Med; 1999 Feb; 54(2):46-62. PubMed ID: 10079679
[TBL] [Abstract][Full Text] [Related]
11. Anagrelide and Mutational Status in Essential Thrombocythemia.
Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A
BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108
[TBL] [Abstract][Full Text] [Related]
12. New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Caldini A; Nozzoli C; Terreni A; Staderini M; Berardi M; Biagioli T; Brogi M; Bosi A
Clin Chem Lab Med; 2016 Jun; 54(6):991-5. PubMed ID: 26581069
[TBL] [Abstract][Full Text] [Related]
13. The emergence of non-secretory multiple myeloma during the non-cytotoxic treatment of essential thrombocythemia: a case report.
Leković D; Gotić M; Mitrović O; Radojković M; Bila J; Dencic-Fekete M; Kraguljac-Kurtović N; Peruničić-Jovanović M; Cokić V
J Med Case Rep; 2013 Sep; 7():224. PubMed ID: 24025541
[TBL] [Abstract][Full Text] [Related]
14. A rare CALR variant mutation and a review of CALR in essential thrombocythemia.
Diep R; Metjian A
J Thromb Thrombolysis; 2018 Apr; 45(3):457-462. PubMed ID: 29411299
[TBL] [Abstract][Full Text] [Related]
15. Diversities of Calreticulin Gene Mutations in Macedonian Patients With Essential Thrombocythemia.
Panovska-Stavridis I; Eftimov A; Ivanovski M; Stojanovic A; Georgievski B; Cevreska L; Dimovski AJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):477-81. PubMed ID: 27521277
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Clinical and Molecular Features Between Patients With Essential Thrombocythemia and Early/Prefibrotic Primary Myelofibrosis Presenting With Thrombocytosis in Taiwan.
Kuo MC; Chuang WY; Chang H; Lin TH; Wu JH; Lin TL; Ou CW; Hung YS; Huang TY; Huang YJ; Wang PN; Shih LY
Am J Clin Pathol; 2023 May; 159(5):474-483. PubMed ID: 36857745
[TBL] [Abstract][Full Text] [Related]
17. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
18. CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.
Dogliotti I; Fava C; Serra A; Gottardi E; Daraio F; Carnuccio F; Giugliano E; Bocchia M; Saglio G; Rege-Cambrin G
Stem Cell Investig; 2017; 4():57. PubMed ID: 28725653
[TBL] [Abstract][Full Text] [Related]
19. Synchronous dual hematological malignancies: new or underreported entity?
Kotchetkov R; Ellison E; McLean J; Pressnail B; Nay D
Hematology; 2018 Oct; 23(9):596-599. PubMed ID: 29874974
[TBL] [Abstract][Full Text] [Related]
20. A Rare Coexistence of Smoldering Multiple Myeloma and JAK2-Positive Myeloproliferative Neoplasm: A Case of Dual Synchronous Hematological Malignancy.
Hammani A; Doghmi O; Allaoui M; Ababou M; Mahtat EM; El Maaroufi H; Doghmi K
Cureus; 2024 Jan; 16(1):e52622. PubMed ID: 38374866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
